Pressmeddelanden från BioPorto

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

BioPorto A/S Appoints Chief Financial Officer 05 feb 21:01

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update 11 dec 2025 17:31

Changes to the Executive Management 24 nov 2025 10:38

Managers’ transactions 24 nov 2025 10:09

BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes 19 nov 2025 07:32

BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth 13 nov 2025 23:13

Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S 13 nov 2025 19:50

BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement 04 nov 2025 22:10

Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs 04 nov 2025 22:08

Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 04 nov 2025 22:07

Progress Update on BioPorto’s Adult Clinical Study 26 sep 2025 10:13

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented 11 sep 2025 08:26

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker 01 sep 2025 18:15

Grant of Warrants 28 aug 2025 12:06

ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.15 aug 2025 07:57

BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth.29 jul 2025 15:28

BioPorto A/S to host an investor webcast on the results for the first half of 2025 28 jul 2025 16:52

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.28 jul 2025 16:40

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.27 jun 2025 09:20

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US 12 jun 2025 19:56

Grant of Warrants 10 jun 2025 16:20

BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy 08 maj 2025 08:19

Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.28 apr 2025 18:28

Grant of Warrants 28 apr 2025 16:41

BioPorto A/S to host first quarter 2025 earnings webcast for investors 25 apr 2025 14:07

BioPorto announces completion of an oversubscribed directed offering of 25 million new shares raising DKK 33.5 million 25 apr 2025 13:55

Managers’ transactions 25 apr 2025 13:45

BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes 15 apr 2025 08:31

Correction: Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S 15 apr 2025 08:15

Private placement of 25,000,000 new shares fully subscribed – gross proceeds of DKK 33.5 million, to BioPorto A/S 14 apr 2025 16:55

BioPorto A/S initiates a private placement of up to 25,000,000 new shares at market price. The Board of Directors has received advance indications for the full offering which is expected to raise proceeds of DKK 33.5 million.11 apr 2025 16:45

Resolutions of the Annual General Meeting 01 apr 2025 14:34

Updated biographies for board candidates at the upcoming Annual General Meeting 20 mar 2025 08:15

Notice convening the Annual General Meeting in BioPorto A/S 20 mar 2025 08:03

BioPorto announces the Annual Report for 2024 19 mar 2025 19:15

BioPorto announces guidance for 2025 and aspirations for 2026 towards 2029 04 mar 2025 21:28

BioPorto A/S announces Jens Due Olsen as a Board of Directors candidate intending to appoint Jens Due Olsen as Chair, along with updates on other candidates 27 feb 2025 18:05

Strengthening of Investor Focus – BioPorto enters Market Maker Agreement with Danske Bank & appoints New Head of Investor Relations 29 jan 2025 18:16

BioPorto A/S appoints new interim Chairman of the Board 23 jan 2025 13:23

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals 06 jan 2025 18:16

Preliminary Financial Figures for the 2024 Fiscal Year 16 dec 2024 18:53

BioPorto commences process to appoint new Chair of the Board of Directors 14 nov 2024 08:50

BioPorto Announces Interim Results and Business Update for the Third Quarter and Nine Months of Fiscal 2024 12 nov 2024 09:57

BioPorto A/S to Host Third Quarter 2024 Earnings Webcast 08 nov 2024 17:03

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences 04 nov 2024 18:44

Grant of Warrants 29 okt 2024 08:56

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital 28 okt 2024 16:26

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests 23 okt 2024 17:15

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference 22 okt 2024 08:04

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL 21 okt 2024 17:15

BioPorto A/S Announces Changes to the US Commercial Organization 10 okt 2024 16:17

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study 15 aug 2024 08:58

Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi 15 aug 2024 08:37

BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 07 aug 2024 13:04

BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting 30 jul 2024 17:15

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms 29 jul 2024 16:35

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo 26 jul 2024 17:15

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo 17 jul 2024 17:50

Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker 11 jul 2024 17:15

Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury 04 jul 2024 17:54

Grant of Warrants 01 jul 2024 17:30

BioPorto confirms market acceptance of NGAL products with US standing order. 24 jun 2024 09:55

Managers’ transactions 24 jun 2024 09:52

Changes of number of shares and votes in BioPorto A/S 18 jun 2024 08:14

Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.17 jun 2024 19:04

BioPorto A/S initiates a private placement of 50,000,000 new shares at market price. 30 maj 2024 14:17

BioPorto A/S Appoints Chief Financial Officer 08 maj 2024 08:21

First Quarter 2024: Strong growth in US sales of The NGAL Test 07 maj 2024 13:10

BioPorto A/S Appoints President and CEO of BioPorto Inc.02 maj 2024 13:53

BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting 30 apr 2024 15:46

Resolutions of Annual Geneal Meeting 23 apr 2024 19:20

Grant of warrants 10 apr 2024 13:22

BioPorto A/S Appoints Chief Legal Officer 05 apr 2024 15:46

New Board Candidate for the upcoming Annual Geneal Meeting 04 apr 2024 11:07

Notice convening the Annual General Meeting in BioPorto A/S 04 apr 2024 09:43

Correction: BioPorto Announces Annual Results for 2023 04 apr 2024 08:29

BioPorto Announces Annual Results for 2023 02 apr 2024 10:47

BioPorto A/S to Host Annual Earnings Webcast 02 apr 2024 07:54

BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer 22 feb 2024 07:31

BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 20 feb 2024 08:28

Roche Diagnostics and BioPorto expand collaboration 19 feb 2024 07:41

BioPorto A/S to host investor meetings on 22 February 2024 09 jan 2024 19:42

BioPorto implements changes to the Executive Management.09 dec 2023 18:12

Managers’ transactions 08 dec 2023 17:02

FDA Clears First Test to Identify Hospitalized Children at Risk for Acute Kidney Injury (AKI) 08 dec 2023 08:13

BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år 07 dec 2023 22:22

BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years 04 dec 2023 20:00

Resignation of Director 01 nov 2023 17:40

BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference 01 nov 2023 08:31

BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 31 okt 2023 15:17

BioPorto provides interim Q3 results and revised 2023 Financial Guidance.20 okt 2023 18:14

BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call 22 sep 2023 18:59

Grant of Warrants 19 sep 2023 15:16

BioPorto Initiates Search for new CFO as Neil Goldman Resigns 11 sep 2023 08:30

BioPorto Provides Update on NGAL Test Regulatory Pathway 28 aug 2023 17:32

BioPorto to Participate in Upcoming Investor Conferences 01 aug 2023 08:48

BioPorto Announces Interim Results for the First Six Months of 2023 07 jul 2023 14:55

BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call 29 jun 2023 08:11

BioPorto Announces Submission of Response to FDA Additional Information Letter 28 jun 2023 15:50

Managers’ transactions